|
% |
Unaudited six months ended 30 June 2025 R’000 |
Unaudited six months ended 30 June 2024 R’000 |
Re-presented* Audited six months ended 31 December 2024 R’000 |
|
|
Healthcare services revenue |
8.7 |
2 422 694 |
2 229 240 |
2 296 813 |
|
Healthcare services operating costs |
(9.6) |
(2 145 196) |
(1 956 988) |
(2 139 863) |
|
IFRS 16: Lease reversals |
43 180 |
36 949 |
41 095 |
|
|
Healthcare services operating profit |
3.7 |
320 678 |
309 201 |
198 045 |
|
Healthcare retail revenue |
(14.2) |
1 856 142 |
2 163 612 |
1 949 623 |
|
Healthcare retail cost of sales |
12.2 |
(1 515 250) |
(1 725 552) |
(1 563 362) |
|
Healthcare retail operating costs |
24.5 |
(263 288) |
(348 663) |
(256 691) |
|
Healthcare retail operating profit |
(13.2) |
77 604 |
89 397 |
129 570 |
|
Total healthcare operating profit |
(0.1) |
398 282 |
398 598 |
327 615 |
|
Loss on sale of investment |
– |
(5) |
– |
|
|
Dividends received |
143 |
– |
– |
|
|
Fair value gains |
– |
1 769 |
380 |
|
|
Other income |
130 |
– |
3 052 |
|
|
Compensation for impairment of property and equipment |
– |
– |
64 402 |
|
|
Impairment of assets and loans |
– |
(274 198) |
(226 667) |
|
|
Write off of intangible assets |
(9 421) |
(6 060) |
(3 792) |
|
|
Reversal of impairment of loans |
33 |
– |
– |
|
|
Net finance and investment income |
(14 849) |
(26 823) |
(15 192) |
|
|
– Finance and investment income |
21 512 |
20 949 |
25 123 |
|
|
– Finance costs: Lease liabilities |
(7 278) |
(10 697) |
(8 017) |
|
|
– Finance costs |
(29 083) |
(37 075) |
(32 298) |
|
|
Share-based payment (expense)/income |
(12 594) |
2 834 |
(6 520) |
|
|
Share of profits/(losses) from associates and joint ventures |
2 600 |
(11 550) |
(2 199) |
|
|
Profit before depreciation and amortisation |
330.8 |
364 324 |
84 565 |
141 079 |
|
Depreciation |
(27.6) |
(62 337) |
(48 839) |
(55 884) |
|
Right of use assets depreciation |
(68.2) |
(32 287) |
(19 197) |
(31 282) |
|
Amortisation of intangible assets |
(11.3) |
(108 689) |
(97 695) |
(104 642) |
|
Profit/(loss) before taxation |
298.4 |
161 011 |
(81 166) |
(50 729) |
|
Taxation expense |
(9.3) |
(52 914) |
(48 403) |
(62 786) |
|
Profit/(loss) for the period from continuing operations |
183.4 |
108 097 |
(129 569) |
(113 515) |
|
(Loss)/profit from discontinued operations net of tax |
(6 544) |
18 848 |
(5 639) |
|
|
Profit on sale of subsidiary |
5 101 |
– |
– |
|
|
Profit/(loss) for the period ended |
106 654 |
(110 721) |
(119 154) |
|
|
Other comprehensive (loss)/income |
(5 555) |
(8 432) |
9 512 |
|
|
Comprehensive net income/(loss) for the period |
(184.8) |
101 099 |
(119 153) |
(109 642) |
|
Attributable to: |
||||
|
Equity holders of the Parent |
91 509 |
(126 812) |
(116 353) |
|
|
Non-controlling interest |
9 590 |
7 659 |
6 711 |
|
|
101 099 |
(119 153) |
(109 642) |
||
| * | The supplementary information operating performance (non-IFRS measure) table has been re-presented to separately disclose discontinued operations which were previously included in continuing operations for the comparative periods presented. |